FDA of­fers a pro­pos­al to help gener­ic drug de­vel­op­ers get si­mul­ta­ne­ous ap­provals in mul­ti­ple mar­kets

The FDA re­vealed Thurs­day that it’s of­fer­ing a pro­pos­al to the In­ter­na­tion­al Coun­cil on Har­mon­i­sa­tion — ICH — to bet­ter har­mo­nize sci­en­tif­ic and tech­ni­cal stan­dards for gener­ic drugs.

The plan is to let gener­ic drug de­vel­op­ers im­ple­ment a sin­gle glob­al drug de­vel­op­ment pro­gram, with com­mon el­e­ments of ap­pli­ca­tions to file, which will al­low for si­mul­ta­ne­ous ap­provals in mul­ti­ple mar­kets.

“This would make it eas­i­er for de­vel­op­ers that would oth­er­wise on­ly seek gener­ic drug ap­proval in one re­gion to al­so seek ap­proval in the Unit­ed States, in­creas­ing com­pe­ti­tion in Amer­i­ca. And it would al­so make it eas­i­er for de­vel­op­ers that would oth­er­wise on­ly seek gener­ic drug ap­proval in the US mar­ket to gain ac­cess to oth­er mar­kets,” FDA com­mis­sion­er Scott Got­tlieb said in a state­ment.

More specif­i­cal­ly, FDA is propos­ing that ICH de­vel­op a se­ries of guide­lines on stan­dards for demon­strat­ing bioe­quiv­a­lence for both non-com­plex and com­plex dosage forms, and drug prod­ucts. FDA ex­pects that ICH will re­view FDA’s pro­pos­al and that the ICH As­sem­bly will en­dorse the pro­pos­al at its next meet­ing in No­vem­ber 2018.

As far as ar­eas for po­ten­tial con­sid­er­a­tion, There­sa Mullin, as­so­ciate di­rec­tor for strate­gic ini­tia­tives at FDA, told at­ten­dees of the As­so­ci­a­tion for Ac­ces­si­ble Med­i­cines con­fer­ence in Sep­tem­ber, of the pos­si­bil­i­ties:

  • A se­ries of ICH guide­lines on bioe­quiv­a­lence stan­dards for sim­ple and com­plex dosage forms;
  • Asur­vey of ex­ist­ing ICH guide­lines for up­dat­ing as need­ed to in­cor­po­rate rec­om­men­da­tions for gener­ic drugs.

“These ac­tiv­i­ties in­clude pur­su­ing op­por­tu­ni­ties like a har­mo­nized bioe­quiv­a­lence study de­sign that could be ex­pand­ed to in­clude ad­di­tion­al study arms to ac­com­mo­date more than one ref­er­ence prod­uct for bridg­ing pur­pos­es,” Got­tlieb added.

Man­u­fac­tur­ing spec­i­fi­ca­tions may al­so dif­fer be­tween coun­tries.

“For ex­am­ple, right now a spe­cif­ic drug may need to be test­ed un­der dif­fer­ent dis­so­lu­tion meth­ods and ac­cep­tance cri­te­ria to sat­is­fy both the FDA and the Eu­ro­pean Med­i­cines Agency’s reg­u­la­to­ry re­quire­ments,” Got­tlieb said, not­ing that the lack of har­mo­niza­tion across ba­sic com­po­nents of gener­ic drug de­vel­op­ment re­duces the op­por­tu­ni­ties for gener­ic drug de­vel­op­ers to use their da­ta and in­for­ma­tion across mul­ti­ple ap­pli­ca­tions in dif­fer­ent ju­ris­dic­tions.

AAM said in a state­ment that it sup­ports FDA in this ini­tia­tive and looks for­ward to work­ing close­ly with them on it.

FDA al­so re­cent­ly con­duct­ed a pre­lim­i­nary analy­sis that found there are sig­nif­i­cant op­por­tu­ni­ties to ex­pand the avail­abil­i­ty and in­crease mar­ket com­pe­ti­tion for gener­ic drugs be­yond their cur­rent mar­kets.

In par­tic­u­lar, FDA ex­plored the ques­tion of whether there ap­pear to be op­por­tu­ni­ties for coun­tries to gain ac­cess to gener­ic drugs not cur­rent­ly avail­able. In ad­di­tion to the US mar­ket, FDA used da­ta avail­able from 2017 for a sam­pling of nine oth­er coun­tries in­clud­ing five in the EU (France, Ger­many, Greece, Poland and the UK), Japan, Cana­da, Switzer­land and Aus­tralia.

“First, FDA looked at whether the top 100 drugs dis­pensed in the U.S. were al­so avail­able in those nine oth­er coun­tries and found that all of the nine ex­pe­ri­enced some lack of avail­abil­i­ty of these drugs, which ranged from 5 (of 100) un­avail­able in Cana­da to 25 (of 100) un­avail­able in Japan,” Got­tlieb said.

“Next, FDA ex­am­ined the set of ap­prox­i­mate­ly 400 gener­ic drugs with the low­est vol­umes sold in the U.S. used as a proxy for low­est lev­el of U.S. avail­abil­i­ty. FDA found that on­ly 35 per­cent of these drugs were avail­able in the oth­er nine coun­tries and 65 per­cent of these drugs ap­pear to be un­avail­able,” he added.


First pub­lished here. reg­u­la­to­ry fo­cus is the flag­ship on­line pub­li­ca­tion of the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety (RAPS), the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care and re­lat­ed prod­ucts, in­clud­ing med­ical de­vices, phar­ma­ceu­ti­cals, bi­o­log­ics and nu­tri­tion­al prod­ucts. Email news@raps.org for more in­for­ma­tion.

Author

Zachary Brennan

managing editor, RAPS

John Hood [file photo]

UP­DATE: Cel­gene and the sci­en­tist who cham­pi­oned fe­dra­tinib's rise from Sanofi's R&D grave­yard win FDA OK

Six years after Sanofi gave it up for dead, the FDA has approved the myelofibrosis drug fedratinib, now owned by Celgene.

The drug will be sold as Inrebic, and will soon land in the portfolio at Bristol-Myers Squibb, which is finalizing a deal to acquire Celgene.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: AveX­is sci­en­tif­ic founder was axed — and No­var­tis names a new CSO in wake of an ethics scan­dal

Now at the center of a storm of controversy over its decision to keep its knowledge of manipulated data hidden from regulators during an FDA review, Novartis CEO Vas Narasimhan has found a longtime veteran in the ranks to head the scientific work underway at AveXis, where the incident occurred. And the scientific founder has hit the exit.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

Ab­b­Vie gets its FDA OK for JAK in­hibitor upadac­i­tinib, but don’t look for this one to hit ex­ecs’ lofty ex­pec­ta­tions

Another big drug approval came through on Friday afternoon as the FDA OK’d AbbVie’s upadacitinib — an oral JAK1 inhibitor that is hitting the rheumatoid arthritis market with a black box warning of serious malignancies, infections and thrombosis reflecting fears associated with the class.

It will be sold as Rinvoq — at a wholesale price of $59,000 a year — and will likely soon face competition from a drug that AbbVie once controlled, and spurned. Reuters reports that a 4-week supply of Humira, by comparison, is $5,174, adding up to about $67,000 a year.

The top 10 fran­chise drugs in bio­phar­ma his­to­ry will earn a to­tal of $1.4T (tril­lion) by 2024 — what does that tell us?

Just in case you were looking for more evidence of just how important Amgen’s patent win on Enbrel is for the company and its investors, EvaluatePharma has come up with a forward-looking consensus estimate on what the list of top 10 drugs will look like in 2024.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

ICER blasts FDA, PTC and Sarep­ta for high prices on DMD drugs Em­flaza, Ex­ondys 51

ICER has some strong words for PTC, Sarepta and the FDA as the US drug price watchdog concludes that as currently priced, their respective new treatments for Duchenne muscular dystrophy are decidedly not cost-effective.

The final report — which cements the conclusions of a draft issued in May — incorporates the opinion of a panel of 17 experts ICER convened in a public meeting last month. It also based its analysis of Emflaza (deflazacort) and Exondys 51 (eteplirsen) on updated annual costs of $81,400 and over $1 million, respectively, after citing “incorrect” lower numbers in the initial calculations.

The key dates for KRAS watch­ers through the end of the year — the trail is nar­row and risks are ex­treme

There’s nothing quite like a big patent win when it comes to burnishing your prospects in the pipeline. And for Amgen, which seems to have rescued Enbrel for a run to 2029, the cheering section on Wall Street is now fixed on AMG 510 and a key rival.

And it didn’t take much data to do it. 

There was the first snapshot of a handful of patients, with a 50% response rate. Then came word that Amgen researchers are also tracking responses in different cancers, at least one in colorectal cancer and appendiceal too. 

Bain's Or­ly Mis­han joins Pfiz­er's neu­ro spin­out Cerev­el; On­colyt­ic virus biotech taps Sil­la­Jen ex­ec He­le­na Chaye as CEO

→ Bain Capital is deploying one of its top investors to Cerevel Therapeutics, steering a $350 million-plus neuro play carved out of Pfizer. Orly Mishan — a co-founder and principal of Bain’s life sciences unit — was involved in the partnership that birthed the biotech spinout in the first place. As Cerevel’s first chief business officer, she is tasked with corporate development, program management as well as technical operations. 

UP­DAT­ED: Sci­en­tist-CEO ac­cused of im­prop­er­ly us­ing con­fi­den­tial in­fo from uni­corn Alec­tor

The executive team at Alector $ALEC has a bone to pick with scientific co-founder Asa Abeliovich. Their latest quarterly rundown has this brief note buried inside:

On June 18, 2019, we initiated a confidential arbitration proceeding against Dr. Asa Abeliovich, our former consulting co-founder, related to alleged breaches of his consulting agreement and the improper use of our confidential information that he learned during the course of rendering services to us as our consulting Chief Scientific Officer/Chief Innovation Officer. We are in the early stage of this arbitration proceeding and are unable to assess or provide any assurances regarding its possible outcome.

There’s no explicit word in the filing on what kind of confidential info was involved, but the proceeding got started 2 days ahead of Abeliovich’s IPO.

Abeliovich, formerly a tenured associate professor at Columbia, is a top scientist in the field of neurodegeneration, which is where Alector is targeted. More recently, he’s also helped start up Prevail Therapeutics as the CEO, which raised $125 million in an IPO. And there he’s planning on working on new gene therapies that target genetically defined subpopulations of Parkinson’s disease. Followup programs target Gaucher disease, frontotemporal dementia and synucleinopathies.

But this time Abeliovich is the CEO rather than a founding scientist. And some of their pipeline overlaps with Alector’s.

Abeliovich and Prevail, though, aren’t taking this one lying down.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

Chi­na has be­come a CEO-lev­el pri­or­i­ty for multi­na­tion­al phar­ma­ceu­ti­cal com­pa­nies: the trend and the im­pli­ca­tions

After a “hot” period of rapid growth between 2009 and 2012, and a relatively “cooler” period of slower growth from 2013 to 2015, China has once again become a top-of-mind priority for the CEOs of most large, multinational pharmaceutical companies.

At the International Pharma Forum, hosted in March in Beijing by the R&D Based Pharmaceutical Association Committee (RDPAC) and the Pharmaceutical Research and Manufacturers of America (PhRMA), no fewer than seven CEOs of major multinational pharmaceutical firms participated, including GSK, Eli Lilly, LEO Pharma, Merck KGaA, Pfizer, Sanofi and UCB. A few days earlier, the CEOs of several other large multinationals attended the China Development Forum, an annual business forum hosted by the research arm of China’s State Council. It’s hard to imagine any other country, except the US, having such drawing power at CEO level.